Floatz logo

Atengenal

Metastatic Prostate Cancer

Burzynski Research InstitutePhase 2Dormant
C
33/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
73/ 100

Competitive context

252 Active assets in the Metastatic Prostate Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4BBB
LEUPROLIDE
Mayo Clinic
Phase 4BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

Atengenal is also rated in:

brain glioblastomaDormant
C
Indicative ·
38 / 100
View asset →
brain neoplasmDormant
C
Indicative ·
38 / 100
View asset →
non-Hodgkin lymphomaDormant
C
Indicative ·
35 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →